Swedish biotech company Anocca has entered a non-exclusive licensing agreement with EmendoBio to use the latter’s OMNI-A4 nuclease, a gene editing technology [that cleaves chains of nucleotides in nucleic acids into smaller units].
This strategic move is set to expedite developing and manufacturing Anocca’s pipeline of T cell receptor-engineered T cell (TCR-T) therapies, targeting difficult-to-treat solid cancers.
Go deeper with GlobalData
The latest development comes after Anocca received good manufacturing practice compliance certification and a manufacturing licence from regulators in Sweden for its cell therapy production facility.
Anocca CEO and co-founder Reagan Jarvis stated: “Integrating EmendoBio’s nuclease into our manufacturing process supports Anocca’s aim of generating the highest-quality cell therapy products.
“This next-generation gene editing system provides the precision and efficiency needed to scale out production of our growing libraries of TCR-T products in a high-precision manufacturing process.
See Also:
“We are excited to work with EmendoBio to develop gene-edited TCR-T cell therapies as we prepare for our first clinical programme targeting the KRAS driver mutation in a hard-to-treat solid cancer.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataEmendoBio’s technology is expected to significantly enhance Anocca’s manufacturing expertise.
It will also aid the company in delivering tailored therapies to patients more rapidly, focusing on the genetic causes of hard-to-treat cancer types.
The licensed gene editing technology is part of EmendoBio’s nuclease suite designed for high activity and specificity within cell therapy applications.
EmendoBio director Dr Ei Yamada stated: “This non-exclusive licensing agreement marks a significant milestone in the field of T cell therapy.
“Together with Anocca, we are embracing the shared vision of harnessing the potential of gene editing and cellular therapies to make a profound impact on patient outcomes. Our combined expertise will unlock novel avenues for therapeutic development and push the boundaries of what’s possible in advanced medicine.”
In May 2023, Anocca secured Skr400m ($38.9m) in an equity financing round to develop next-generation cell therapies for cancer on an industrial scale.
AMF and Mellby Gård led the funding round.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
